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http://dx.doi.org/10.1016/j.chembiol.2013.08.003At the plenary session of this year’s con-
ference on Plant-Based Vaccines, Anti-
bodies, and Pharmaceuticals, in Verona,
Italy, all eyes were on Israeli company
Protalix Biotherapeutics. In May 2012,
the US Food and Drug Administration
(FDA)-approved Protalix’s plant-cell-
expressed enzyme replacement therapy
Elelyso (taliglucerase alfa) for type 1
Gaucher’s disease, which is an orphan
disease. Protalix’s approval was another
step towards market acceptance and
commercial viability for transgenic plant-
based drugs and an inflection point in a
field that has struggled with regulatory
issues and public fears of transgenic
plants corrupting the food supply.In recent years, a handful of biotechs have been turning plants
into drug factories to create proteins that could not be made
otherwise, or to make them more cheaply.In recent years, a handful of biotechs
have been turning plants into drug fac-
tories to create proteins that could not
be otherwise made or to make them
more cheaply—but they are using almost
diametrically different strategies to do so.
‘‘We are the first ever to have a recom-
binant plant organism approved by the
FDA,’’ says David Aviezer, Ph.D., Protalix
president and CEO. ‘‘We are the pioneers
in the field. On one hand, we are using
plant cells. We are not using recombinant
plants. There is a real difference between
what we are doing and what was being
attempted in the 90s.’’
Protalix BioTherapeutics is a publicly
traded company of about 250 employees.
The company uses a platform called
ProCellEX to grow active ingredients in
transgenic carrot and tobacco cells in
disposable bioreactors.
A New Use for Mashed Carrots
Gaucher’s disease is an inherited meta-
bolic disorder where people lack the
enzyme glucocerebrosidase, which helpsrid the body of a fatty substance called
glucosylceramide. Ninety-five percent
of the people who develop Gaucher’s
disease have type 1, in which fatty
accumulations cause enlarged liver,
spleen, bone damage, bruising, and
anemia. Gaucher’s disease may affect
between 45,000 and 60,000 people
worldwide, and about 1 in 855 Ashkenazi
Jews. Aviezer estimates about 6000–
6500 Gaucher’s disease patients get
enzyme replacement therapy.
According to Aviezer, Eleyso costs an
estimated $200,000 annually versus Gen-
zyme’s Cerezyme (imiglucerase; made
from Chinese hamster ovary cells) and
Shire’s Vpriv (velaglucerase alfa; madefrom human cell lines), which both cost
about $250,000 a year. In a ‘‘tight collab-
oration,’’ Pfizer markets taliglucerase
alfa in the United States, Israel, and Brazil.
The European Medicines Agency rejected
Elelyso in favor of Vpriv because Shire
had 10 year marketing exclusivity in Eu-
rope and Elelyso was effectively similar.
Enzyme replacement therapy is admin-
istered intravenously, usually at biweekly
intervals. Protalix is developing an oral
version of Elelyso, which is now in phase
1 according to Professor Ari Zimran,
M.D., director of the Gaucher’s Clinic at
Jerusalem’s Shaare Zedek Hospital.
According to Aviezer, using conven-
tional equipment and processes makes
meeting regulatory requirements easier.
‘‘Our mode is to keep it simple and
inexpensive,’’ Aviezer says. The company
uses disposable bioreactors so they
don’t have to clean them between
cycles. ‘‘The capital costs for setting up
a facility are dramatically lower than with
Chinese hamster or mammalian cells,’’
says Aviezer. ‘‘We see similar numbersChemistry & Biology 20, August 22, 2013when we go to operational cost. It varies
fromprotein to protein.’’ A cost advantage
in producing protein from plants rather
than mammalian cells is that inputs are
sugar and water—not animal-based
growth factors. Risk of contamination
risk is lower, as mammalian viruses
cannot affect plant cells. (An acute
shortage of imiglucerase—20% of prior
global supply—occurred in 2009 as a
result of viral contamination of Genzyme’s
production facility).
Protalix has an oral drug for Fabry
disease, PRX 102, in phases 1/2, and
PRX-105, a biodefense drug, in phase 1.
The company just signed a $280 million
agreement with the Brazilian Health
Agency to produce its Gaucher’s disease
medication.
Transgenic Rice Comes to Kansas
Ventria Bioscience grows its recombi-
nant protein-based therapeutics in trans-
genic rice. The company’s headquarters
and R&D are located in Fort Collins,
Colorado, and its bioprocessing facility
is in Kansas.
‘‘We had the idea of utilizing plants
as a host for biopharmaceuticals and
bioreagants and using the sun as the
energy source and the plant as the
factory,’’ says Scott Deeter, Ventria
Bioscience CEO and cofounder. ‘‘The
challenge has been to put together the
key pieces of technology.’’ Ventria can
make multisubunit molecules, mono-
clonal antibodies, fusion proteins, and
enzymes with its ExpressTec recombi-
nant expression platform. The company
licensed plant expression technology
from the University of California at Berke-
ley; the University of California, Davis;
Washington State University; and the
University of California, San Diego.
Ventria chose rice as a host because
of its safety profile. Because it is self-
pollinating, rice doesn’t need wind or
insects to reproduce. Proteins in rice
endosperm store up to 3 years in con-
trolled conditions, and the companyª2013 Elsevier Ltd All rights reserved 969
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Good Manufacturing Practices (cGMP).
VEN100, Ventria’s lead product now in
phase 2 trials, is a recombinant human
lactoferrin, which is found in human
breast milk and is used to reduce the
risk of antibiotic-associated diarrhea
(AAD). Currently no safe or effective
prophylaxis exists. According to Deeter,
AAD costs the US healthcare system
between $6 billion and $7.5 billion a
year. He estimates that VEN100 targets
a market of 2.8 million at-risk hospitalized
patients.
In 2012, Ventria conducted a phase
2 clinical trial of VEN100 in 22 long-term
care patients at Johns Hopkins Bayview
Medical Center who were vulnerable to
repeated antibiotic-related Clostridium
difficile infections; this type of infection is
responsible for one in four cases of AAD.
In this study, 92% of the placebo group
developed AAD versus 44% of the test
group. ‘‘The next step is to validate it in
a larger patient population and larger pro-
spective blinded study,’’ says Dr. William
Greenough III, M.D., professor of medi-
cine at Johns Hopkins, who ran the trial..
He pointed out that since Pepto-Bismol
was invented at the turn of the 20th
century, there have been no new medica-
tions invented for diarrhea. ‘‘We know we
are at the end of the antibiotic era,’’ says
Greenough. ‘‘We see this every day in
medicine.’’
Ventria has been awarded $6.5 million
in grants from the National Institutes
of Health (NIH) through the small
business innovative research (SBIR)
program. Ventria is also developing
products for chemotherapy-induced
diarrhea, inflammatory bowel disease,
osteoporosis, and liver disease as
well as developing a serum albumin
and doing contract manufacturing of
biopharmaceuticals.
The company is collaborating with the
NIH and the Centers for Disease Control
and Prevention (CDC) on zoonotic vac-
cines. The company received an addi-
tional $1 million SBIR grant to work with
the Department of Health and Human
Services, the CDC, and the NIH to
develop a Lyme disease vaccine. Ventria
recently started a collaboration with
the University of Southern California to
develop a fusion protein between proin-
sulin and transferrin—potentially a treat-
ment for diabetes.970 Chemistry & Biology 20, August 22, 2013But Ventria has had a tough road to
hoe. According to the company, its initial
test transgenic rice fields drew objections
from organic farming groups in California.
Ventria also made a collaboration agree-
ment with Northwest Missouri State
University, but Anheuser Busch in
St. Louis, concerned about the amount
of state funding requested by the univer-
sity to complete the biotech center where
Ventria would be a tenant, opposed the
project. Instead, Ventria set up a bio-
processing facility in a part of Kansas
where rice was not grown and is curren-
tly cultivating a about 200 acres there.
According to Deeter, Ventria uses a
segregated and controlled supply sys-
tem, including dedicated equipment,
storage, and processing facilities, to
ensure quality and regulatory compliance.
‘‘The key is high yields and product per
acre,’’ says Deeter. ‘‘In our early years,
we developed a suspension cell culture
system as well. It did not enable
cost -effective product yields, so it was
not economic to scale-up.’’ Deeter cited
Canadian company Medicago, another
plant-based biologics company which
targeted vaccines and was recently sold
for $357 million. ‘‘Ventria has invested
a fourth of the capital and achieved
50 times more product.’’ says Deeter.
Transgenic Soybeans in a
Greenhouse
In Charlotte, North Carolina, two scien-
tists coincidentally named Ken—Kenneth
Piller, Ph.D., and Kenneth Bost, Ph.D. —
have turned soybeans into transgenic
protein factories. Their 4 person com-
pany, Soymeds (http://www.soymeds.
com), is developing a bioterror vaccine,
a protein to downregulate immune
response for multiple sclerosis, called a
toleragen, and thyroglobulin, a therapeu-
tic diagnostic.
According to Piller, soybeans are
natural storage systems. They produce
proteins that are well tolerated and can
be delivered orally in soymilk or as an
injectable. ‘‘We think soybeans are a
great proof of concept because they
are protein-rich,’’ said Piller. ‘‘Any cell
cultures are low protein.’’ About 20 soy-
bean plants contained in a greenhouse
could make a gram of target protein.
Piller and Bost received initial funding
from the NIH while at the University of
North Carolina at Charlotte. Soymedsª2013 Elsevier Ltd All rights reservedjust got a 3 year, $1.5 million SBIR grant
to develop a diagnostic using homoge-
nous soybean-produced thyroglobulin.
According to Piller, thyroglobulin is an
extremely large protein and therefore
difficult to produce. The only current
source of thyroglobulin, which costs
$100 a milligram, is cadaver thyroids.
Thyroglobulin purified this way is highly
variable, so tests aren’t standardized
and the same test by the same company
must be used for yearly checkups.
Soymeds thinks they can use soybeans
to develop a cheaper, more uniform
thyroglobulin protein.
Soymeds is developing a soy-derived
therapeutic for treatment of multiple
sclerosis. Myelin antigens are difficult to
express but Soymeds’ MS antigen can
be delivered in a drinkable soy milk
formulation. This therapeutic was tested
successfully in mice. The company is
also developing a vaccine against
staphlococcal enterotoxin B (SEB), a
potential biowarfare agent, which was
successful when tested in mouse and
pig models.
There are still technical issues. While
virus-like particles are very immunogenic,
for example, subunit vaccines against
diarrheal diseases require an oral adju-
vant—something to helpmediate a strong
immune reponse—and there are still no
good adjuvants that can be used with
oral vaccines.
Piller realizes that the public has a
negative perception of genetically modi-
fied organisms. ‘‘The reason is that
Americans don’t see a benefit coming
out of it,’’ says Piller. ‘‘Wouldn’t it be
great if a plant-derived therapeutic could
save the lives of millions of children or
stop and reverse the effects of multiple
sclerosis? Oftentimes new therapeutics
treat symptoms rather than diseases.
We are attempting to target the root of
the disease.’’
Piller recalls a discussion about bio-
similars versus biobetters at the Verona
conference. ‘‘A strong feeling among
several leaders in the field is that really,
you need a biobetter to advance this
technology to the marketplace,’’ says
Piller. ‘‘We are trying to fill gaps for prob-
lems that currently exist for which there
is no solution.’’Wendy Wolfson (wendywolfson@nasw.org) is a
science writer based in Southern California.
